Pregnant women mount strong immune response to single H1N1 flu vaccine dose.Byline: ANI Washington, Nov 3 (ANI): Healthy pregnant women tend to develop a strong immune response immune response n. An integrated bodily response to an antigen, especially one mediated by lymphocytes and involving recognition of antigens by specific antibodies or previously sensitized lymphocytes. following just one dose of 2009 H1N1 influenza vaccine influenza vaccine Flu vaccine A vaccine recommended for those at high risk for serious complications from influenza: > age 65; Pts with chronic diseases of heart, lung or kidneys, DM, immunosuppression, severe anemia, nursing home and other chronic-care , according to according to prep. 1. As stated or indicated by; on the authority of: according to historians. 2. In keeping with: according to instructions. 3. initial results from an ongoing clinical trial. Sponsored by the National Institute of Allergy and Infectious Diseases infectious diseases: see communicable diseases. (NIAID NIAID National Institute of Allergy and Infectious Diseases. ) of the National Institutes of Health, the trial involved a preliminary analysis of blood samples taken 21 days post-vaccination from a subgroup of 50 pregnant women. "For pregnant women, who are among the most vulnerable to serious health problems from 2009 H1N1 infection, these initial results are very reassuring," said NIAID Director Dr. Anthony S. Fauci. "The immune responses seen in these healthy pregnant women are comparable to those seen in healthy adults at the same time point after a single vaccination, and the vaccine has been well tolerated," he added. The researchers found that in 25 women who received a single 15-microgram dose of the vaccine, the H1N1 flu vaccine The flu vaccine is a vaccine to protect against the highly variable influenza virus. The annual flu kills an estimated 36,000 people in the United States. elicited an immune response likely to be protective in 92 percent, or 23 of 25, of these women. In 25 women who received a single 30-microgram dose of the vaccine, the H1N1 flu vaccine elicited an immune response likely to be protective in 96 percent, or 24 of 25, of these women. The trial began on Sept. 9 and reached its target enrollment of 120 volunteers in mid-October. All participants are between 18 to 39 years old and began the study in their second or third trimester (14 to 34 weeks) of pregnancy. On entering the study, the participants were divided at random into two groups: half are receiving two doses of a 15-microgram vaccine and the other half are receiving two doses of a 30-microgram vaccine. The two injections of vaccine are spaced three weeks apart. Safety is being monitored closely in the trial, by the study investigators and by an independent panel of experts known as a safety monitoring committee. To date, the vaccine appears to be well tolerated, and no safety concerns related to the vaccine have arisen. (ANI) Copyright 2009 Asian News International The Asian News International (ANI) agency provides multimedia news to China and 50 bureaus in India. It covers virtually all of South Asia since its foundation and presently claims, on its official website, to be the leading South Asia-wide news agency. (ANI) - All Rights Reserved. Provided by Syndigate.info an Albawaba.com company |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion